The important role of simplified acute physiological score-3 in early corticosteroid treatment for patients with acute respiratory distress syndrome

doi:10.3969/j.issn.1006-7795.2021.06.003

Abstract

Abstract: Objective To investigate the role of Simplified Acute Physiological Score-3 (SAPS-3) in spotting who was likely to benefit from early corticosteroid treatment in patients with acute respiratory distress syndrome (ARDS). Methods Electronic intensive care unit collaborative research database (eICU-CRD) was used to extract data about moderate or severe ARDS patients. After the cut-off value of SAPS-3 was identified, accordingly, the enrolled patients were divided into two groups. Propensity score matching analysis (PSMA) was used to remove confounding factors before comparing the effect of early corticosteroid treatment in ARDS patients. Results There were 3 234 ARDS patients with early corticosteroid treatment and 1 122 ARDS patients without this treatment. After propensity score matching analysis (PSMA), the data showed that ARDS patients with SAPS-3>70 had a shorter duration of mechanical ventilation after early corticosteroid treatment [(5.2±5.6) d vs (6.5±5.9) d, P<0.001), compared with the patients with SAPS-3≤70. There was no difference in mortality whether early corticosteroid treatment was applied or not. Conclusion The ARDS patients with SAPS-3>70 were likely to benefit from early corticosteroid treatment.

Key words: electronic intensive care unit collaborative research database, corticosteroid, acute respiratory distress syndrome, Simplified Acute Physiological Score-3

CLC Number:

Liu Hui, Xiao Jianguo, Hu Xin, Wang Li, Zhou Feihu. The important role of simplified acute physiological score-3 in early corticosteroid treatment for patients with acute respiratory distress syndrome[J]. Journal of Capital Medical University, 2021, 42(6): 915-922.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2021.06.003

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2021/V42/I6/915

References

[1] Villar J, Ferrando C, Martínez D, et al. Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial[J]. Lancet Respir Med, 2020, 8(3): 267-276.
[2] Lewis S R, Pritchard M W, Thomas C M, et al. Pharmacological agents for adults with acute respiratory distress syndrome[J]. Cochrane Database Syst Rev, 2019, 7(7):CD004477.
[3] Mungan İ, Bektaş Ş,Altınkaya Çavuş M, et al. The predictive power of SAPS-3 and SOFA scores and their relations with patient outcomes in the surgical intensive care unit[J]. Turk J Surg, 2019, 35(2):124-130.
[4] 郭晓娟,田国祥,闫小妮,等. eICU合作研究数据库申请及数据提取流程[J]. 中国循证心血管医学杂志, 2019, 11(1): 6-9.
[5] Pollard T J, Johnson A E W, Raffa J D, et al. The eICU Collaborative Research Database, a freely available multi-center database for critical care research[J]. Sci Data, 2018, 5:180178.
[6] Keegan M T, Gajic O, Afessa B. Comparison of APACHE Ⅲ, APACHE Ⅳ, SAPS 3, and MPMOⅢ and influence of resuscitation status on model performance[J]. Chest, 2012, 142(4): 851-858.
[7] Nassar A P, Malbouisson L M, Moreno R. Evaluation of Simplified Acute Physiology Score 3 performance: a systematic review of external validation studies [J]. Crit Care, 2014, 18(3):R117.
[8] 杜斌. 急性呼吸窘迫综合征的柏林定义:究竟改变了什么? [J]. 首都医科大学学报, 2013, 34(2): 201-203.
[9] Matera M G, Rogliani P, Bianco A, et al. Pharmacological management of adult patients with acute respiratory distress syndrome[J]. Expert Opin Pharmacother, 2020, 21(17):2169-2183.
[10] Fan E, Brodie D, Slutsky A S. Acute respiratory distress syndrome: advances in diagnosis and treatment [J]. JAMA, 2018, 319(7):698-710.
[11] Ye Z, Wang Y, Colunga-Lozano L E, et al. Efficacy and safety of corticosteroids in COVID-19 based on evidence for COVID-19, other coronavirus infections, influenza, community-acquired pneumonia and acute respiratory distress syndrome: a systematic review and meta-analysis[J]. CMAJ, 2020, 192(27):E756-E767.
[12] Zhan Y, Shang J, Gu Y, et al. Efficacy of corticosteroid in patients with COVID-19: a multi-center retrospective study and meta-analysis[J]. J Med Virol, 2021, 93(7): 4292-4302.
[13] RECOVERY Collaborative Group, Horby P, Lim W S, et al. Dexamethasone in Hospitalized Patients with Covid-19[J]. N Engl J Med, 2021, 384(8):693-704.
[14] Menezes R C, Ferreira I B B, Carmo T A, et al. Are prognostic tools losing accuracy? Development and performance of a novel age-calibrated severity scoring system for critically ill patients[J]. PLoS One, 2020, 15(11):e0240793.
[15] Shadnia S, Zamani N, Hassanian-Moghaddam H, et al. Prognostic value of cortisol and thyroid function tests in poisoned patients admitted to toxicology ICU[J]. World J Emerg Med, 2018, 9(1):51-55.
[16] Meduri G U, Rochwerg B. Point: should corticosteroids be routine treatment in early ARDS? Yes[J]. Chest, 2021, 159(1):25-29.
[17] 董红建,谭捷.糖皮质激素联合参芪扶正注射液辅治重症社区获得性肺炎致ARDS患者效果观察及对血清炎性因子、血气指标影响[J].临床误诊误治,2019,32(11):25-29.
[18] Nicolaides N C, Kyratzi E, Lamprokostopoulou A, et al. Stress, the stress system and the role of glucocorticoids[J].
Neuroimmunomodulation, 2015, 22(1-2): 6-19.
[19] Mokra D, Mikolka P, Kosutova P, et al. Corticosteroids in acute lung injury: the dilemma continues[J]. Int J Mol Sci, 2019, 20(19):4765.
[20] Villar J, Confalonieri M, Pastores S M, et al. Rationale for prolonged corticosteroid treatment in the acute respiratory distress syndrome caused by coronavirus disease 2019[J]. Crit Care Explor, 2020, 2(4): e0111.
[21] Torres A, Sibila O, Ferrer M, et al. Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial[J]. JAMA, 2015, 313(7): 677-686.
[22] WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Sterne J A C, Murthy S, et al. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis[J]. JAMA, 2020, 324(13): 1330-1341.
[23] Annane D, Pastores S M, Rochwerg B, et al. Guidelines for the diagnosis and management of critical illness-related corticosteroid insufficiency (CIRCI) in critically ill patients (Part I): Society of Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESICM) 2017[J]. Intensive Care Med, 2017, 43(12): 1751-1763.
[24] Oh D K. Corticosteroids in acute respiratory distress syndrome: outcomes obscured by mortality[J]. Korean J Intern Med, 2021, 36(1):65-66.